Lipocine Net Income
| LPCN Stock | USD 8.89 0.40 4.71% |
As of the 10th of February, Lipocine secures the Risk Adjusted Performance of 0.2617, mean deviation of 5.01, and Downside Deviation of 4.96. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Lipocine, as well as the relationship between them.
Lipocine Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 7.7635 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income | 7.5 K | 7.9 K | |
| Net Income From Continuing Ops | 9.6 K | 10.1 K | |
| Net Loss | -12.4 M | -13 M | |
| Net Income Per E B T | 1.06 | 1.09 |
Lipocine | Net Income | Build AI portfolio with Lipocine Stock |
Evaluating Lipocine's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Lipocine's fundamental strength.
Latest Lipocine's Net Income Growth Pattern
Below is the plot of the Net Income of Lipocine over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Lipocine financial statement analysis. It represents the amount of money remaining after all of Lipocine operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Lipocine's Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lipocine's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 8.35 K | 10 Years Trend |
|
Net Income |
| Timeline |
Lipocine Net Income Regression Statistics
| Arithmetic Mean | (9,562,709) | |
| Geometric Mean | 966,637 | |
| Coefficient Of Variation | (91.78) | |
| Mean Deviation | 7,793,099 | |
| Median | (10,758,636) | |
| Standard Deviation | 8,777,052 | |
| Sample Variance | 77T | |
| Range | 21M | |
| R-Value | 0.09 | |
| Mean Square Error | 81.4T | |
| R-Squared | 0.01 | |
| Significance | 0.72 | |
| Slope | 164,364 | |
| Total Sum of Squares | 1232.6T |
Lipocine Net Income History
Other Fundumenentals of Lipocine
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Lipocine Net Income component correlations
Lipocine Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Lipocine is extremely important. It helps to project a fair market value of Lipocine Stock properly, considering its historical fundamentals such as Net Income. Since Lipocine's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lipocine's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lipocine's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Pharmaceuticals sector continue expanding? Could Lipocine diversify its offerings? Factors like these will boost the valuation of Lipocine. Expected growth trajectory for Lipocine significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Lipocine data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.02) | Revenue Per Share | Quarterly Revenue Growth 5.954 | Return On Assets | Return On Equity |
Understanding Lipocine requires distinguishing between market price and book value, where the latter reflects Lipocine's accounting equity. The concept of intrinsic value - what Lipocine's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Lipocine's price substantially above or below its fundamental value.
Understanding that Lipocine's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lipocine represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Lipocine's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Lipocine 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Lipocine's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Lipocine.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Lipocine on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Lipocine or generate 0.0% return on investment in Lipocine over 90 days. Lipocine is related to or competes with OSR Holdings, Adlai Nortye, BioLineRx, GeoVax Labs, Edesa Biotech, ProMIS Neurosciences, and Eterna Therapeutics. Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the... More
Lipocine Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Lipocine's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Lipocine upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 4.96 | |||
| Information Ratio | 0.3007 | |||
| Maximum Drawdown | 33.09 | |||
| Value At Risk | (7.33) | |||
| Potential Upside | 15.95 |
Lipocine Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lipocine's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Lipocine's standard deviation. In reality, there are many statistical measures that can use Lipocine historical prices to predict the future Lipocine's volatility.| Risk Adjusted Performance | 0.2617 | |||
| Jensen Alpha | 2.15 | |||
| Total Risk Alpha | 1.38 | |||
| Sortino Ratio | 0.4105 | |||
| Treynor Ratio | (8.81) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Lipocine's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Lipocine February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.2617 | |||
| Market Risk Adjusted Performance | (8.80) | |||
| Mean Deviation | 5.01 | |||
| Semi Deviation | 3.28 | |||
| Downside Deviation | 4.96 | |||
| Coefficient Of Variation | 317.21 | |||
| Standard Deviation | 6.78 | |||
| Variance | 45.91 | |||
| Information Ratio | 0.3007 | |||
| Jensen Alpha | 2.15 | |||
| Total Risk Alpha | 1.38 | |||
| Sortino Ratio | 0.4105 | |||
| Treynor Ratio | (8.81) | |||
| Maximum Drawdown | 33.09 | |||
| Value At Risk | (7.33) | |||
| Potential Upside | 15.95 | |||
| Downside Variance | 24.64 | |||
| Semi Variance | 10.73 | |||
| Expected Short fall | (5.83) | |||
| Skewness | 0.9675 | |||
| Kurtosis | 1.0 |
Lipocine Backtested Returns
Lipocine is moderately volatile given 3 months investment horizon. Lipocine has Sharpe Ratio of 0.3, which conveys that the firm had a 0.3 % return per unit of risk over the last 3 months. We were able to break down twenty-eight different technical indicators, which can help you to evaluate if expected returns of 2.09% are justified by taking the suggested risk. Use Lipocine Mean Deviation of 5.01, risk adjusted performance of 0.2617, and Downside Deviation of 4.96 to evaluate company specific risk that cannot be diversified away. Lipocine holds a performance score of 24 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of -0.24, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Lipocine are expected to decrease at a much lower rate. During the bear market, Lipocine is likely to outperform the market. Use Lipocine value at risk, as well as the relationship between the skewness and day median price , to analyze future returns on Lipocine.
Auto-correlation | 0.00 |
No correlation between past and present
Lipocine has no correlation between past and present. Overlapping area represents the amount of predictability between Lipocine time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Lipocine price movement. The serial correlation of 0.0 indicates that just 0.0% of current Lipocine price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 0.06 | |
| Residual Average | 0.0 | |
| Price Variance | 1.95 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Lipocine Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Lipocine reported net income of 8.35 K. This is 100.0% lower than that of the Pharmaceuticals sector and 99.99% lower than that of the Health Care industry. The net income for all United States stocks is 100.0% higher than that of the company.
Lipocine Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lipocine's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lipocine could also be used in its relative valuation, which is a method of valuing Lipocine by comparing valuation metrics of similar companies.Lipocine is currently under evaluation in net income category among its peers.
Lipocine Current Valuation Drivers
We derive many important indicators used in calculating different scores of Lipocine from analyzing Lipocine's financial statements. These drivers represent accounts that assess Lipocine's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Lipocine's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 55.6M | 33.8M | 14.7M | 26.1M | 30.0M | 28.5M | |
| Enterprise Value | 55.0M | 30.7M | 9.9M | 19.8M | 22.8M | 21.7M |
Lipocine ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Lipocine's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Lipocine's managers, analysts, and investors.Environmental | Governance | Social |
Lipocine Institutional Holders
Institutional Holdings refers to the ownership stake in Lipocine that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Lipocine's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Lipocine's value.| Shares | Tower Research Capital Llc | 2025-06-30 | 673 | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 575 | Ubs Group Ag | 2025-06-30 | 475 | Caldwell Sutter Capital Inc | 2025-06-30 | 471 | Group One Trading, Lp | 2025-06-30 | 162 | Sbi Securities Co Ltd | 2025-06-30 | 67.0 | Tidemark Llc | 2025-06-30 | 59.0 | Fmr Inc | 2025-06-30 | 0.0 | Jpmorgan Chase & Co | 2025-06-30 | 0.0 | Vanguard Group Inc | 2025-06-30 | 224.9 K | Blackrock Inc | 2025-06-30 | 89.3 K |
Lipocine Fundamentals
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.21 | ||||
| Profit Margin | (1.27) % | ||||
| Operating Margin | (29.34) % | ||||
| Current Valuation | 33.56 M | ||||
| Shares Outstanding | 5.55 M | ||||
| Shares Owned By Insiders | 2.84 % | ||||
| Shares Owned By Institutions | 18.66 % | ||||
| Number Of Shares Shorted | 146.2 K | ||||
| Price To Earning | 15.80 X | ||||
| Price To Book | 3.44 X | ||||
| Price To Sales | 10.90 X | ||||
| Revenue | 11.2 M | ||||
| Gross Profit | 4.32 M | ||||
| EBITDA | (1.11 M) | ||||
| Net Income | 8.35 K | ||||
| Cash And Equivalents | 37.4 M | ||||
| Cash Per Share | 0.42 X | ||||
| Total Debt | 438.62 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 22.23 X | ||||
| Book Value Per Share | 2.61 X | ||||
| Cash Flow From Operations | (1.22 M) | ||||
| Short Ratio | 0.64 X | ||||
| Earnings Per Share | (1.02) X | ||||
| Target Price | 10.88 | ||||
| Number Of Employees | 16 | ||||
| Beta | 1.01 | ||||
| Market Capitalization | 47.14 M | ||||
| Total Asset | 22.51 M | ||||
| Retained Earnings | (199.77 M) | ||||
| Working Capital | 20.81 M | ||||
| Current Asset | 29.41 M | ||||
| Current Liabilities | 1.57 M | ||||
| Net Asset | 22.51 M |
About Lipocine Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lipocine's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lipocine using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lipocine based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Lipocine
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lipocine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lipocine will appreciate offsetting losses from the drop in the long position's value.Moving together with Lipocine Stock
Moving against Lipocine Stock
| 0.9 | HPQ | HP Inc | PairCorr |
| 0.62 | MSFT | Microsoft | PairCorr |
| 0.57 | BRK-A | Berkshire Hathaway | PairCorr |
| 0.47 | VLCN | Volcon Inc Symbol Change | PairCorr |
| 0.37 | MMM | 3M Company | PairCorr |
The ability to find closely correlated positions to Lipocine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lipocine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lipocine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lipocine to buy it.
The correlation of Lipocine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lipocine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lipocine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lipocine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Will Pharmaceuticals sector continue expanding? Could Lipocine diversify its offerings? Factors like these will boost the valuation of Lipocine. Expected growth trajectory for Lipocine significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Lipocine data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.02) | Revenue Per Share | Quarterly Revenue Growth 5.954 | Return On Assets | Return On Equity |
Understanding Lipocine requires distinguishing between market price and book value, where the latter reflects Lipocine's accounting equity. The concept of intrinsic value - what Lipocine's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Lipocine's price substantially above or below its fundamental value.
Understanding that Lipocine's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lipocine represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Lipocine's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.